Producer
Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC (Amman Jordan; London Stock Exchange: HIK; NYSE: WHL; ~$3.1B revenue) is a major US generic injectable pharmaceutical manufacturer primarily through its Hikma Pharmaceuticals USA (formerly Roxane Laboratories) division acquired in 2016 for $2.65B. US injectable manufacturing: Columbus OH (Hikma Columbus — formerly Roxane; large sterile injectable campus) and Eatontown NJ (Hikma Eatontown). Hikma produces morphine sulfate injection, fentanyl citrate injection, and hydromorphone HCl injection as Schedule II controlled substance generics for US hospitals. Hikma is the largest pure-play injectable pharmaceutical company by volume in the US generics market. Jordan-headquartered and London-listed but the business is majority US generic injectables — an unusual corporate structure for what is effectively a critical US hospital drug supplier.
3
Inputs supplied
1
Goods downstream
2
Facilities
0
Stories
What they make
3 inputs Hikma Pharmaceuticals PLC supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
pharmaceutical
Generic Oncology Injectable Vials (Cisplatin, Carboplatin, Paclitaxel) →
pharmaceutical
Injectable opioid vials (morphine, hydromorphone, fentanyl IV) →
pharmaceutical
Injectable Hospital Antibiotics (Vancomycin, Pip-Tazo, Cefepime) →
Where it shows up
Goods downstream
Essential goods that depend on something Hikma Pharmaceuticals PLC makes — pick one to see the full supply chain.
Where they make it
2 facilities
Hikma Pharmaceuticals Columbus OH (formerly Roxane Laboratories) →
USOhio · manufacturing
Large sterile injectable manufacturing campus in Columbus OH; formerly Roxane Laboratories (acquired by Hikma 2016). Produces morphine sulfate injection, fentanyl citrate injection, and hydromorphone HCl injection as Schedule II generics. Columbus is Hikma's largest US injectable manufacturing site and a primary source of generic injectable opioids for US hospital formularies. Also manufactures non-opioid injectable generics for US hospitals.
Hikma Pharmaceuticals Eatontown NJ →
USNew Jersey · manufacturing
Hikma Pharmaceuticals injectable manufacturing site in Eatontown NJ; produces injectable pharmaceutical generics including controlled substance injectables for US hospital market. Secondary Hikma US injectable site complementing Columbus OH primary campus.
What else they do
Business segments
The company's full revenue map — where this supply-chain role fits within their broader business.
Injectables (US and International)
55%Branded (MENA Region)
23%Generics (US Oral)
22%
Intelligence
What's known
Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.
Concentration2023
Hikma Pharmaceuticals PLC is headquartered in Amman, Jordan and listed on the London Stock Exchange (HIK) and NYSE (WHL) — yet is the largest pure-play generic injectable pharmaceutical company by volume in the US hospital market, supplying a significant fraction of US hospital formulary drugs including Schedule II controlled substance injectable opioids. Hikma entered the US injectable market through acquisitions: RMS Laboratories (2003), Elkins-Sinn (2004), and most significantly Roxane Laboratories (Columbus OH) for $2.65 billion in 2016. Roxane, founded in 1885 in Columbus, was one of the oldest pharmaceutical manufacturers in the US. Hikma's acquisition of Roxane transformed a Jordanian company into a critical US hospital drug supplier. A company headquartered in Amman Jordan, listed in London, and founded by a Jordanian family (Al Hikma means 'wisdom' in Arabic) supplies the morphine sulfate injections used in American hospital emergency departments, ICUs, and operating rooms. US hospital drug procurement officers routinely buy injectable opioids from a company few Americans know is Jordanian-owned.
Hikma Pharmaceuticals PLC ↗Did you know2016
Hikma Pharmaceuticals — headquartered in Amman, Jordan, listed on the London Stock Exchange, and named after the Arabic word for 'wisdom' — is the largest pure-play generic injectable pharmaceutical company in the United States by production volume. Every US hospital's pharmacy stocks Hikma-manufactured morphine drips, cisplatin chemotherapy vials, and IV antibiotics from the company's Columbus, Ohio facility — a campus that most hospital pharmacists know only as the former home of Roxane Laboratories (founded 1885, owned by Boehringer Ingelheim until 2016). The $2.65B acquisition of Roxane made a Jordanian family-controlled company a critical component of the US hospital drug supply chain, with essentially no public visibility.
Hikma Pharmaceuticals PLC ↗Origin2023
Hikma was founded in 1978 by Samih Darwazah, a Jordanian pharmacist who had previously worked for Eli Lilly in the US. He returned to Jordan, founded the company with the mission of making affordable branded medicines for the Arab world, and took it public in London in 2005. When Darwazah's son Mazen Darwazah led the $2.65B acquisition of Roxane Laboratories in 2016, Hikma transformed overnight from a MENA-focused branded generic company into one of the largest US hospital injectable manufacturers — a strategic pivot that the founder almost certainly could not have envisioned. The Columbus OH Roxane campus now employs more people in Ohio than the entirety of Hikma's original Jordanian operations.
Hikma Pharmaceuticals PLC ↗Capacity2023
During the 2023 US cisplatin and carboplatin shortage triggered by the Intas Ahmedabad facility shutdown, Hikma was one of three manufacturers (alongside Pfizer/Hospira and Fresenius Kabi) that the FDA contacted to urgently increase oncology injectable production. Hikma's Columbus OH facility had the sterile fill-finish capacity and platinum-chemistry expertise to accelerate cisplatin vial production. Hikma's position as an oncology injectable manufacturer was not widely known to oncologists managing the shortage — most were aware of Pfizer and Fresenius Kabi as the 'backup suppliers' without knowing that a Jordanian company's Ohio facility was equally critical. FDA drug shortage database; oncology pharmacy shortage management reports 2023.
American Society of Health-System Pharmacists ↗